Diffuse reduction of myocardial beta-adrenoceptors in hypertrophic cardiomyopathy: a study with positron emission tomography

Medical Research Council (MRC) Cyclotron Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, England, United Kingdom.

OBJECTIVES. This study was conducted to determine the myocardial beta-adrenoceptor density as a marker of sympathetic function in patients with hypertrophic cardiomyopathy and normal control subjects. BACKGROUND. Although some cases of hypertrophic cardiomyopathy are familial with an autosomal dominant pattern of inheritance, there remains a substantial proportion of cases in which neither a family history nor genetic abnormalities can be demonstrated. Additional abnormalities, both genetic and acquired, may be important in the phenotypic expression of this condition. Clinical features of the disease and metabolic studies suggest an increased activity of the sympathetic nervous system. METHODS. Eleven patients with hypertrophic cardiomyopathy, none of whom had previously received beta-blocking drugs, and eight normal control subjects underwent positron emission tomography to evaluate regional left ventricular beta-adrenoceptor density and myocardial blood flow using carbon-11-labeled CGP 12177 and oxygen-15-labeled water as tracers. Plasma catecholamines were also measured. RESULTS. Mean (+/- SD) myocardial beta-adrenoceptor density was significantly less in the hypertrophic cardiomyopathy group than in the control group (7.70 +/- 1.86 vs. 11.50 +/- 2.18 pmol/g tissue, p < 0.001). Myocardial blood flow was similar in both groups (0.91 +/- 0.22 vs. 0.91 +/- 0.21 ml/min per g, p = NS). The distribution of beta-adrenoceptor density was uniform throughout the left ventricle in both groups. In the hypertrophic cardiomyopathy group, there was no correlation between regional wall thickness and myocardial beta-adrenoceptor density. There were no significant differences in either plasma norepinephrine or epinephrine concentrations between the two groups. CONCLUSIONS. There is a diffuse reduction in myocardial beta-adrenoceptor density in patients with hypertrophic cardiomyopathy in the absence of significantly elevated circulating catecholamine concentrations. This most likely reflects downregulation of myocardial beta-adrenoceptors secondary to increased myocardial concentrations of norepinephrine and is consistent with the hypothesis that cardiac sympathetic drive is increased in this condition.

This article has been cited by other articles:

				J. Jimenez and J. C. Tardiff Abnormal heart rate regulation in murine hearts with familial hypertrophic cardiomyopathy-related cardiac troponin T mutations Am J Physiol Heart Circ Physiol, February 1, 2011; 300(2): H627 - H635. [Abstract] [Full Text] [PDF]

				O. Gaemperli, R. Liga, N. Spyrou, S. D. Rosen, R. Foale, J. S. Kooner, O. E. Rimoldi, and P. G. Camici Myocardial {beta}-adrenoceptor down-regulation early after infarction is associated with long-term incidence of congestive heart failure Eur. Heart J., July 2, 2010; 31(14): 1722 - 1729. [Abstract] [Full Text] [PDF]

				S. F. Nagueh and J. J. Mahmarian Noninvasive Cardiac Imaging in Patients With Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2410 - 2422. [Abstract] [Full Text] [PDF]

				R. L. Verrier, A. V. Tolat, and M. E. Josephson T-Wave alternans for arrhythmia risk stratification in patients with idiopathic dilated cardiomyopathy J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2225 - 2227. [Full Text] [PDF]

				P. Sipola, E. Vanninen, H. J. Aronen, K. Lauerma, S. Simula, P. Jaaskelainen, M. Laakso, K. Peuhkurinen, J. Kuusisto, and J. T. Kuikka Cardiac Adrenergic Activity Is Associated with Left Ventricular Hypertrophy in Genetically Homogeneous Subjects with Hypertrophic Cardiomyopathy J. Nucl. Med., April 1, 2003; 44(4): 487 - 493. [Abstract] [Full Text] [PDF]

				N. Spyrou, S. D. Rosen, F. Fath-Ordoubadi, R. Jagathesan, R. Foale, J. S. Kooner, and P. G. Camici Myocardial beta-adrenoceptor densityone month after acute myocardial infarctionpredicts left ventricular volumes at six months J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1216 - 1224. [Abstract] [Full Text] [PDF]

				P G Camici Imaging of cardiac adrenergic innervation Heart, September 1, 2002; 88(3): 209 - 210. [Full Text] [PDF]

				J. Delforge, D. Mesangeau, F. Dolle, P. Merlet, C. Loc'h, M. Bottlaender, R. Trebossen, and A. Syrota In Vivo Quantification and Parametric Images of the Cardiac {beta}-Adrenergic Receptor Density J. Nucl. Med., February 1, 2002; 43(2): 215 - 226. [Abstract] [Full Text] [PDF]

				I. Carrio Cardiac Neurotransmission Imaging J. Nucl. Med., July 1, 2001; 42(7): 1062 - 1076. [Abstract] [Full Text] [PDF]

				U. Schotten, K. Filzmaier, B. Borghardt, S. Kulka, F. Schoendube, C. Schumacher, and P. Hanrath Changes of beta -adrenergic signaling in compensated human cardiac hypertrophy depend on the underlying disease Am J Physiol Heart Circ Physiol, June 1, 2000; 278(6): H2076 - H2083. [Abstract] [Full Text] [PDF]

				M. Schafers, H. Lerch, T. Wichter, C. G. Rhodes, A. A. Lammertsma, M. Borggrefe, F. Hermansen, O. Schober, G.u. Breithardt, and P. G. Camici Cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia J. Am. Coll. Cardiol., July 1, 1998; 32(1): 181 - 186. [Abstract] [Full Text] [PDF]

				M. Schafers, D. Dutka, C. G. Rhodes, A. A. Lammertsma, F. Hermansen, O. Schober, and P. G. Camici Myocardial Presynaptic and Postsynaptic Autonomic Dysfunction in Hypertrophic Cardiomyopathy Circ. Res., January 23, 1998; 82(1): 57 - 62. [Abstract] [Full Text] [PDF]

				D C Lefroy Grand Rounds - Hammersmith Hospital: Cardiac arrest and hypertrophic cardiomyopathy BMJ, November 12, 1994; 309(6964): 1277 - 1279. [Full Text]